The Analysis Of The Short-term Efficacy And The Related Factors Of Visual Prognosis Of Conbercept In The Treatment Of Macular Edema Associated With BRVO

Objective:By comparing the changes of various observation indicators before and after treatment,We observe the short-term efficacy of Conbercept in the treatment of macular edema secondary to branch retinal vein occlusion,and explore the relevant indicators that can predict visual outcome and macular edema recurrence.Methods:A retrospective analysis of 49 patients(50 eyes)with macular edema secondary to BRVO from September 2016 to January 2019 in the Department of Ophthalmology of the Second Hospital of Jilin University,conducted a self-controlled study.Patients were treated with Conbercept0.5mg/0.05ml intravitreal injection by the same surgeon.After one initial injection,they were followed up monthly and treated followed by pro re nata(1+PRN).Indicators of patients for best corrected visual acuity(BCVA),central retinal thickness(CRT),average retinal thickness,retinal volume,the number of inner and outer retina hyperreflective foci(HF),the integrity of the external limiting membrane,the integrity of ellipsoid zone and subretinal fluid before treatment and after treatment(1m,2m,3m,4m,5m,6m)was observed and the efficacy before and after treatment were analyzed.According to the BCVA at 6 months after treatment,patients was divided into a batter visual acuity group(BCVA≥0.5)and a poor visual acuity group(BCVA<0.5)to analyze the relevant indicators of visual prognosis.At 12 months,patients without additional injection for the last 3 months were placed in the resolved group and patients with additional injection were placed in the recurrence group to analyze the relevant indicators of the recurrence of macular edema.SPSS23.0 statistical analysis software was used for data analysis.Results:Efficacy analysis showed that BCVA,CRT,average retinal thickness,retinal volume,number of outer retinal hyperreflective foci,number of inner retinal hyperreflective foci,and subretinal fluid after treatment were statistically significant compared with before treatment(P<0.001).No severe ocular or systemic complications were found in all patients during the follow-up period.Univariate analysis showed that factors associated with visual outcome included age(t=-2.364,P=0.022),baseline BCVA(t=-5.328,P<0.001),CRT(t=-3.946,P<0.001),retina average thickness(t=-3.226,P=0.002),retinal volume(t=-2.302,P=0.026),the number of outer retinal hyperreflective foci(t=-2.191,P=0.033),the number of inner retinal hyperreflective foci(t=-3.029,P=0.004),the integrity of outer limiting membrane(X~2=16.099,P<0.001).Multivariate analysis found that baseline BCVA,number of outer retinal hyperreflective foci,and the integrity of external limiting membrane were used as predictors of visual outcome at 6 months after treatment(P=0.023,0.028,0.048).The shudy aslo showed that factor associated with recurrence of macular edema was the integrity of external limiting membrane(P=0.036).Conclusion:1.Conbercept is safe and effective in treating macular edema caused by branch retinal vein occlusion,which can significantly improve vision and reduce macular edema.2.Baseline best corrected visual acuity,the number of outer retina hyperreflective foci and the integrity of external limiting membrane were predictors of visual outcome of macular edema secondary to retinal branch vein occlusion in patients with BRVO.3.The integrity of external limiting membrane was a factor affecting the recurrence of macular edema in patients with BRVO.